Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

Learn more about:
Related Clinical Trial
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

Official Title

Natural History Study of Children and Adults With Adrenocortical Cancer

Brief Summary


      Adrenocortical cancer (ACC) is a rare tumor. The prognosis is very poor for people with
      advanced stages of ACC. Some people may live with ACC for years; others live for just months.
      Treatment options for ACC often do not work well. Researchers want to study the clinical
      course of the disease. They want to understand how adrenocortical cancer appear on imaging
      scans, how they respond to therapies, and the best treatment for them.


      To gain a better understanding of adrenal cancer.


      People ages 2 and older with ACC who are enrolled in NCI protocol 19-C-0016


      Participants will be screened with a review of their medical records, tumor scans, and cancer
      test results and reports.

      Participants may have CT and other scans. For the scans, they will lie in a machine that
      takes pictures of the body. They may have blood tests. They may have a 24-hour urine
      collection. They may be asked to sign a new consent form for some of these tests.

      Participants will complete paper or electronic surveys. The surveys will ask about the
      effects of cancer on their emotional, physical, and behavioral well-being.

      Participants will receive recommendations about how to manage their issues and potential
      treatment options for their cancer.

      Participants home physician will be contacted every 6 to 12 months to collect medical
      information such as test results and scans.

      Participants may be asked to return to the NIH every 6 to 12 months for follow-up tests.

      Participants will contact study staff if there are any changes in their tumor.

      Participants will be followed on this study for life.

Detailed Description


        -  Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million
           people per year. It has a very poor prognosis with an overall 5-year mortality rate of
           75-90% and an average survival from the time of diagnosis of 14.5 months. Approximately
           10% of ACC cases are associated with a hereditary cancer predisposition syndrome.

        -  The treatment of choice for a localized primary or recurrent tumor is surgical
           resection. Patients with recurrent or metastatic disease are infrequently curable by
           surgery alone.

        -  As with most solid tumors, chemotherapy options have limited benefit, although
           platinumbased therapies have response rates of 25 to 30%. To date no targeted therapy
           has been shown to be of any value in this disease. The role of neoadjuvant and adjuvant
           therapies, including systemic chemotherapy and radiotherapy, remains poorly defined and
           has been reported to have only a modest or no therapeutic effect.

        -  The natural history of ACC can vary greatly with some patients surviving only months
           while others can live with disease for years. The basis for these differing clinical
           presentations is not known. While one cannot exclude an immune or other host component
           as responsible for the diverse clinical courses, it is also possible that there may be a
           genetic basis for this phenomenon.

        -  Patients with rare tumors seek expert advice in the management of their care. A natural
           history study would establish a more formal mechanism for such referrals, while allowing
           the systematic collection of epidemiologic, genomic, molecular data.


      -Characterize the natural history of adrenocortical cancer (ACC). Data will include patient
      demographics, clinical characteristics, patterns of disease progression, response or lack of
      response to therapeutic interventions, disease recurrence and overall survival.


        -  Subjects with documented ACC

        -  Age greater than or equal to 2 years old.


        -  This protocol is a subprotocol to protocol 19C0016 Natural History and Biospecimen
           Accrual Study for Children and Adults with Rare Solid Tumors . After enrollment on the
           master protocol and undergoing evaluations detailed in the master protocol, patients
           will be enrolled on this subprotocol specific for ACC.

        -  Medical history will be collected from medical records and patients followed throughout
           the course of their illnesses, with particular attention to patterns of disease
           recurrence and progression, response to therapies, duration of responses and hormone
           production in patients with hormone production as a manifestation of their disease, and
           patient reported outcomes. Tumor growth rates will also be calculated throughout the
           course of the disease.

Study Type


Primary Outcome

Characterize the natural history of adrenocortical cancer (ACC). Data will include clinical presentation, patterns of disease progression, response or lack of response to therapeutic interventions, disease recurrence and overall survival


Adrenocortical Carcinoma

Study Arms / Comparison Groups

 Cohort 1
Description:  Subjects with confirmed adrenocortical cancer (ACC)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

June 25, 2020

Completion Date

December 31, 2028

Primary Completion Date

December 31, 2028

Eligibility Criteria


          -  Subjects enrolled into NCI protocol 19C0016 Natural History and Biospecimen
             Acquisition Study for Children and Adults with Rare Solid Tumors

          -  Subjects with histologically or cytologically documented ACC.

          -  Age greater than or equal to 2 years old

          -  Ability of subject or parent/guardian to understand and the willingness to sign a
             written consent document.






2 Years - N/A

Accepts Healthy Volunteers



Jaydira Del Rivero, M.D., (240) 753-1971, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

National Cancer Institute (NCI)

Study Sponsor

Jaydira Del Rivero, M.D., Principal Investigator, National Cancer Institute (NCI)

Verification Date

October 3, 2022